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Abstract
Parenting programmes are the recommended treatments of conduct disorders (CD) in children, but little is known about their 
longer term cost-effectiveness. This study aimed to evaluate the population cost-effectiveness of one of the most researched 
evidence-based parenting programmes, the Triple P—Positive Parenting Programme, delivered in a group and individual 
format, for the treatment of CD in children. A population-based multiple cohort decision analytic model was developed to 
estimate the cost per disability-adjusted life year (DALY) averted of Triple P compared with a ‘no intervention’ scenario, 
using a health sector perspective. The model targeted a cohort of 5–9-year-old children with CD in Australia currently 
seeking treatment, and followed them until they reached adulthood (i.e., 18 years). Multivariate probabilistic and univariate 
sensitivity analyses were conducted to incorporate uncertainty in the model parameters. Triple P was cost-effective com-
pared to no intervention at a threshold of AU$50,000 per DALY averted when delivered in a group format [incremental 
cost-effectiveness ratio (ICER) = $1013 per DALY averted; 95% uncertainty interval (UI) 471–1956] and in an individual 
format (ICER = $20,498 per DALY averted; 95% UI 11,146–39,470). Evidence-based parenting programmes, such as the 
Triple P, for the treatment of CD among children appear to represent good value for money, when delivered in a group or an 
individual face-to-face format, with the group format being the most cost-effective option. The current model can be used 
for economic evaluations of other interventions targeting CD and in other settings.
Keywords Population model · Conduct disorder · Children and adolescents · Cost-effectiveness · Parenting programme
Background
Conduct disorder (CD) is common in children and adoles-
cents, with a global prevalence of 3.6% of boys and 1.5% of 
girls aged 5–19 [1]. CD is characterized by, ‘a repetitive and 
persistent pattern of behaviour in which the basic rights of 
others or major age-appropriate societal norms or rules are 
violated’ [2, 3], and is associated with poor educational out-
comes, antisocial and criminal behaviour, substance abuse, 
poor mental health [4, 5], and unemployment [6, 7]. These 
outcomes place a high burden on individuals, families, and 
society [8]. Romeo et al. estimated the mean annual cost of a 
child aged 3–8 with severe antisocial behaviour in the United 
Kingdom (UK) was of £5960 (in 2002 prices), in terms of 
health care, educational, and voluntary sector service use, 
with the greatest cost burden being borne by the family [9]. 
In a UK longitudinal study of children aged 10 with CD, the 
costs at age 28 were 10 times higher than those of children 
with no conduct problems in terms of health service use, 
educational, and justice system costs [10].
Parenting programmes targeted at parents of children 
with conduct problems are the recommended treatments 
of CD [11, 12]. These aim to improve parenting styles and 
parent–child relationships through the reduction of harsh 
and inconsistent parenting practices and promote the use 
of positive incentives and enhanced parent–child commu-
nication [13]. One of the most widely researched parenting 
programmes is the Triple P—Positive Parenting Programme 
[14]. Triple P is a behavioural family intervention, which 
aims to prevent and/or treat severe behavioural, emotional, 
and developmental problems in children and adolescents 
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by enhancing the knowledge, skills, and confidence of par-
ents. It has five levels of increasing intensity, to address the 
range of symptom severity of behavioural problems. This 
intervention comprises a variety of strategies targeting both 
low- and high-risk families, as well as children with prob-
lems in the clinical range, and is one of the most compre-
hensive and systematized parenting programmes available. 
There is evidence supporting the effectiveness [15–17] and 
cost-effectiveness [12, 18] of Triple P on child behaviour 
problems over the short term, but little is known about its 
long-term cost-effectiveness. Bonin et al., modelled the costs 
and longer term savings of parenting programmes that could 
be achieved by reducing the probability of persistent CD 
among children in the UK, and found them to be cost saving 
[19]. This model was, however, a scenario analysis and not a 
full economic evaluation. Furthermore, it did not focus on a 
specific programme, but rather a range of programmes likely 
to be implemented in the UK.
The current study conducted an economic evaluation of 
the Triple P programme, one of the best-researched exam-
ples of evidence-based parenting interventions for the treat-
ment of CD in children. Using the Australian population 
as an example, a health sector perspective was adopted to 
conduct a cost–utility analysis comparing Triple P with a 
‘no intervention’ scenario through the use of modelling 
techniques.
Methods
Economic evaluation framework
This study used a standardized economic evaluation mod-
elling framework developed for evaluating health care 
interventions in the Australian context [20]. The following 
principles underpinned the evaluation: (1) the adoption of 
a health sector perspective, with a focus on government as 
a third-party payer; (2) costs were divided into those accru-
ing to the government and those accruing to individuals and 
their families; (3) data on intervention effectiveness were 
sourced from published literature; (4) a cost–utility analysis 
was performed using disability-adjusted life years (DALYs) 
averted as the primary outcome; (5) a “partial null” compar-
ator was chosen to represent the theoretical level of disease 
that would be present if no interventions for this disease 
were in place [21]; (6) the model used a 2013 reference 
year to match the latest Global Burden of Disease (GBD) 
study [22]; (7) costs were measured in 2013 Australian dol-
lars; (8) a 3% annual discount rate was applied to both costs 
and health outcomes; and (9) we adopted a threshold value 
for cost-effectiveness of $50,000 per DALY, a commonly 
accepted value for money threshold in the Australian set-
ting [20, 23].
Literature search
To find evidence on the effectiveness of Triple P, we per-
formed a search of existing reviews alongside a supple-
mentary search of additional studies. The inclusion criteria 
were: (1) randomized controlled trials or quasi-experimental 
designs; (2) interventions for the treatment of CD (targeting 
children with a diagnosis of CD based on structured clinical 
interviews or cutoffs from disease-specific symptom rating 
scales); (3) studies reporting diagnostic/clinical outcomes at 
follow-up; and (4) interventions that are currently used for 
the treatment of diagnosed CD and would optimally oper-
ate within the Australian mental health system (based on 
advice from a Technical Advisory Panel composed of clini-
cal experts and researchers in the field). This study modelled 
changes in disorder prevalence that would occur with the 
Triple P intervention. As such, we excluded studies meas-
uring changes in CD symptoms (without reporting clinical 
cutoffs) due to difficulties in determining how changes in 
a mean and standard deviation score on a symptom scale 
translate into actual cases of CD. Furthermore, the most 
recent GBD study has one weight for CD, therefore, mak-
ing it impossible to meaningfully model changes in sever-
ity levels, which failed to achieve clinical remission [1]. A 
complete description of the search strategy is presented in 
Section 2 of the Supplementary Appendix.
Intervention effect sizes
From the literature search, the majority of studies were on 
the effectiveness of level 4 Triple P. Of these, two studies 
fulfilled our inclusion criteria [24, 25]. Thus, the group [24] 
and the individual [25] face-to-face formats were selected 
for economic evaluation. Martin and Sanders [24] assessed 
the effectiveness of group Triple P targeting 2–9 year olds, 
while Sanders et al. [25] assessed the effectiveness of indi-
vidual Triple P targeting 3 year olds. Both studies reported 
outcomes at post-test (follow-up time ranged between 
8 weeks after baseline for the group format to 10 weeks after 
baseline for the individual format). Children were assessed 
for conduct problems prior to randomization via a telephone 
consultation. Both studies used the Eyberg Child Behaviour 
Inventory (ECBI) as the outcome measure instrument [26], 
and included children who scored within the clinical range 
of the ECBI intensity scale completed by parents. Group 
Triple P included four weekly two-hour group sessions 
delivered by two psychologists, followed by four weekly 
individual telephone consultations with an average duration 
of 30 min. Parents were also given a workbook. Individual 
Triple P included ten individual sessions, lasting between 60 
and 90 min, delivered by one psychologist.
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We calculated an effect size for each intervention at post-
test, expressed as a relative risk (RR) with a 95% confidence 
interval (CI). This resulted in a relative risk (RR) of: 0.054 
(95% CI 0.003–0.875) for group Triple P and 0.655 (95% 
CI 0.484–0.887) for individual Triple P. We assumed that 
intervention effects at post-test would be maintained up to 
1-year follow-up, as the literature supports the impacts of 
many parenting interventions remain up to 1 year [12, 17, 
27, 28]. A null effect size was assumed thereafter given the 
lack of published evidence on the sustainability of effects 
beyond this period. We assumed that study completers would 
receive a full intervention effect, while dropouts would incur 
a cost, but receive no benefit. In clinical work with children, 
40–60% drop out of treatment prematurely and hence may 
not be receiving the benefits of treatment [29]. We defined 
dropouts as parents who completed less than 20% of the 
intervention [29–31] (Table 1).
Study population and intervention pathway
This study modelled the delivery of group and individual 
Triple P targeting children aged 5–9 years with CD in the 
2013 Australian population. We limited the scope of the 
model to children with CD currently seeking treatment, 
because the intervention does not include a new case find-
ing component, but rather targets parents of children with 
CD who are treatment seeking. This was to reflect current 
practice, since only 60% of children with CD in Australia 
currently access treatment [32]. The selected age group 
reflects the ages comprised in the trials used to provide the 
Table 1  Input parameters and uncertainty ranges used to model health benefits
PSA probabilistic sensitivity analysis, TAP technical advisory panel, NSMHWB 2014 National Survey of Mental Health and Well-Being—child 
component, CI confidence interval
a See Section 3 of the Supplementary Appendix for detailed methods on the calculation of the proportion of intervention completers and dropouts
b As per the 2013 GBD study, case fatality was zero. This is because no estimate of excess mortality due to CD was found in the literature
c Unadjusted disability weight used as the cohort of children modelled in this study was symptomatic and determined appropriate for interven-
tion; therefore, the “weighted” disability weight reported in [22] is an underestimate, given it includes children with a less severe condition
d A follow-up study of Sanders et al. [27] reports the outcomes of individual Triple P at 1- and 3-year follow-up (the control group is dropped 
after post-test) and treatment gains are maintained at both follow-up periods. The initial effect size of the intervention targeting 3 year olds was 
assumed to remain until 6 years of age
Parameters Value and uncertainty range Distribution 
used in PSA
Sources
Patient flowchart
 Proportion of parents offered the interven-
tion
60% (range 40–80) Pert Consultation with TAP
 Proportion of parents taking up the inter-
vention
60% (range 40–80) Pert NSMHWB [32]
 Proportion dropouts (completing 20% of 
intervention (2 sessions)
42% (range 36–49) Pert 1-proportion of completers [29–31]a
 Proportion of parents completing the 
intervention
58% (range 52–65) Pert Own meta-analysis of studies [29–31]a
Epidemiological inputs
 Population 5–9-year-old children with CD 2013 Australian population [38]
 All-cause mortality Single age rates 2013 Australian life tables [39]
 Prevalence of conduct disorder Average 5–18 age range 0.026 (see Sup-
plementary Appendix for age- and sex-
specific estimates)
Beta [22]
 Remission Average 5–18 age range 0.304 (see Sup-
plementary Appendix for age- and sex-
specific estimates)
Gamma [22]
 Incidence Average 5–18 age range 0,009 (see Sup-
plementary Appendix for age- and sex-
specific estimates)
Gamma [22]
 Case fatality 0b [22]
 Disability weight for conduct disorder 0.241 (95% CI 0.159–0.341)c Beta [22]
 Effect size group Triple P 0.054 (95% CI 0.003–0.875)d Lognormal [24]
 Effect size individual Triple P 0.655 (95% CI 0.484–0.887)d Lognormal [25]
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effectiveness estimates. Although the trial on individual 
Triple P targeted children younger than 5 years, our model 
applied a lower age limit of 5 years, as this reflects the age 
at which a diagnosis of CD can be given in clinical practice.
We developed an intervention pathway that was repre-
sentative of routine health services delivered within the Aus-
tralian mental health care system. We assumed the following 
intervention pathway: (1) children with conduct problems 
attended a first visit with a general practitioner (GP) who 
performed an initial assessment prior to making a referral to 
a psychologist; (2) parents were offered either group or indi-
vidual Triple P; and (3) upon treatment completion, the child 
was called for at least one follow-up visit with the GP. The 
following parameters were considered when calculating the 
eligible population that participated in each intervention: (a) 
proportion of children with a CD diagnosis; (b) proportion 
of parents attending an initial GP visit and offered the inter-
vention; (c) proportion of parents taking up the intervention; 
(d) proportion of parents dropping out; and (e) proportion of 
parents completing the intervention. We assumed one parent 
per child. The eligible population was partitioned by sex and 
1-year age groups. All parameters, assumptions, and data 
sources are shown in Table 1 with the patient flowchart pre-
sented in Section 3 of the Supplementary Appendix.
Modelling health benefits
A population-based multiple cohort decision analytic model 
with 1-year cycles was implemented in Excel to simulate the 
disease dynamics with and without the delivery of either 
group or individual therapy over a 13-year time horizon. 
An adapted Dismod-II model, based on a set of differen-
tial equations that describe age-specific epidemiological 
parameters, was used to simulate how a population cohort 
moves between three health states over time—i.e., healthy, 
diseased, and dead [33]. The diseased health state included 
all children with CD, with the prevalence of CD in the initial 
cycle (i.e., at year 0) being based on the current prevalence 
of CD in the 2013 Australian population for each respec-
tive age–sex cohort (see Section 4 of the Supplementary 
Appendix for the corresponding state transition diagram). 
Transitions between health states corresponded with the epi-
demiological parameters: incidence, remission, case fatality, 
Table 2  Input parameters and uncertainty ranges used in the model for costing analysis
MBS Medicare Benefits Schedule
a http ://www2 9.trip lep.net/file s/pdf/Trip leP_Aust rali an_Orde r_Form _for_PRAC TITI ONER S.pdf
b Time and travel costs and other sector costs were not included in the base-case analysis, only used in the sensitivity analysis
c A Pert ± 20% distribution was used for every cost parameter which had uncertainty modelled
Cost parameters (AUS$) Value and uncertainty range Distribution 
used in  PSAc
Sources
Cost of general practitioner (first visit) Government: $97.27 MBS items 2700, 2701, 2715 and 2717 
[40]
Cost of general practitioner (follow-up 
visit)
Government: $70.30 MBS item 2712 [40]
Cost of MBS-funded psychologist single Government: $102.34; private: $18.06 MBS items 80,010 and 80,110 [40]
Cost of MBS-funded psychologist group Government: $25.61; private: $4.52 MBS items 80,020 and 80,120 [40]
Cost workbooks Triple P Triple P practitioner  resourcesa
 Every parent Private: $35
 Every parent group workbook Private: $14.95
Cost uncertainty parameter out-of-pocket 
costs
Range ± 20% of unit costs Pert Protocol
Annual cost of a prevalent case of conduct disorder (for the calculation of cost offsets)
 Health care 5–10 years: $1076.03 (both males and 
females) (range ± 20%)
Pert Own calculations (see Section 5.2 of the 
Supplementary Appendix)
11–18 years: males: $333.01; females: 
$141.03 (range ± 20%)
Pert Own calculations (see Section 5.2 of the 
Supplementary Appendix)
 Other sector  costsb 5–10 years: $2270.85 (both males and 
females) (range ± 20%)
Pert Own calculations (see Section 5.2 of the 
Supplementary Appendix)
11–18 years: males: $10,854.29; females: 
$1027.68 (range ± 20%)
Pert Own calculations (see Section 5.2 of the 
Supplementary Appendix)
Time cost (per hour)b $9.96 (Uprated to 2013 AU$) [35]
Travel cost (per trip)b $24.67 (Uprated to 2013 AU$) [35]
Discount rate 3% [35]
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and all-cause mortality. The model calculated annual transi-
tions between health states for each single year of age–sex 
cohorts starting at age 5 until age 9, until children reached 
adulthood (i.e., 18 years). CD was modelled along the lines 
of a chronic, rather than an episodic disorder. Children were 
assigned a single disability weight for CD (as per the GBD 
studies [1, 34]) based on the presence or the absence of 
the disorder. Comorbidities and longer term consequences 
related to CD were not modelled, as there is no literature 
supporting the longer term effectiveness of Triple P in 
reducing CD or related comorbidities.
Aggregated health outcomes were expressed as DALYs, 
using the disability weight (DW) for CD (0.241) from the 
GBD [34] and the prevalence of CD. Only the morbidity 
component of the DALY was modelled in our study, as there 
was no evidence of a mortality impact. The model produced 
incremental cost-effectiveness ratios (ICERs) reported as the 
net cost per DALY averted. A summary of the epidemio-
logical inputs and their sources are shown in Table 1, and 
detailed methods described in Section 4 of the Supplemen-
tary Appendix.
Costing analysis
The costs of delivering the intervention included: the cost 
of psychological assessment by a GP; the cost of a practi-
tioner to deliver group and individual sessions and telephone 
consultations; and the cost of the workbooks. We assumed 
that the interventions would be delivered through the pub-
licly-financed community sector. Occasionally, participants 
were charged out-of-pocket costs, depending on the type of 
service and the provider. We assumed that the costs for psy-
chological assessment by a GP were fully borne by the gov-
ernment. By contrast, Medicare Benefits Schedule (MBS) 
items for GP consults and group/individual psychologist 
visits were split between: the government (who paid 85% 
of the listed MBS item fee) and the parents (who paid the 
remaining 15% out-of-pocket). We assumed that the cost of 
programme materials was borne by the parents.
Time and travel costs accruing to parents were excluded 
from the base-case analysis, but included in a sensitivity 
analysis. Cost offsets (i.e., treatment costs that are avoided 
due to the reduction in the prevalence of CD), which accrue 
to the health sector, were included in the base-case analysis. 
Broader societal perspectives deemed relevant were included 
in the sensitivity analysis, as large costs associated with CD 
fall outside the health care sector (e.g., criminal justice).
The model assumed that the interventions were fully 
implemented and operating under “steady state” con-
ditions—i.e., trained staff and necessary infrastructure 
were available to deliver the intervention, which operated 
in accordance with its effectiveness potential [35]. A full 
description of the methods used in the costing analysis Ta
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are presented in Section 5 of the Supplementary Appendix. 
All inputs and sources used in the costing analysis are shown 
in Table 2.
Uncertainty and sensitivity analyses
ICERs were calculated by dividing the estimated differ-
ence in costs by the estimated difference in DALYs averted 
through the decrease in prevalence of CD for each inter-
vention compared to “no intervention”. We used Ersatz 
(version 1.31, Sunrise Beach, Australia, available at: http 
://www.epig ear.com/) to perform a probabilistic uncer-
tainty analysis, using Monte Carlo simulation with 3000 
iterations to produce 95% uncertainty intervals (95% UIs) 
around the DALYs averted, net costs, and ICERs. Uncer-
tainty parameters are shown in Tables 1 and 2.
Univariate sensitivity analyses were performed to 
investigate the impact of specific input parameters and 
assumptions on the model outcomes. We modelled the 
individual impact of: (1) excluding cost offsets related to 
the health care sector; (2) including cost offsets related to 
both the health care sector and other non-health sectors; 
Fig. 1  Cost-effectiveness plane 
of the base-case analysis
Fig. 2  Cost-effectiveness 
acceptability curve of the base-
case analysis
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(3) including time and travel costs; (4a) assuming a 50% 
decay rate in effects after year 1 over 5 years (by year 5 the 
RR is close to the null); (4b) assuming intervention effects 
persist over 5 years; (5) assuming dropouts get half of the 
benefit; and (6) applying a 0 and 6% discount rate to both 
costs and benefits. We also conducted a threshold analysis 
to test the impact of varying the effect size of both group 
and individual Triple P.
Results
Table  3 shows the base-case cost-effectiveness results. 
Group Triple P was very cost-effective relative to a threshold 
of $50,000 per DALY averted, with an ICER of $1013. Indi-
vidual Triple P was cost-effective, with an ICER of $20,498 
per DALY averted. Figure 1 presents the results of the base-
case analysis on a cost-effectiveness plane, where estimated 
cost differences are plotted against estimated differences in 
DALYs averted between the intervention and “no interven-
tion”. In this figure, we can see that the uncertainty iterations 
for both interventions lie on the north-east quadrant of the 
plane, where the intervention is more effective and more 
costly than the comparator. Furthermore, the majority of 
the iterations fall below the cost-effectiveness threshold of 
$50,000 per DALY averted. The cost-effectiveness accept-
ability curve (Fig. 2) shows the probability of group and 
individual being cost-effective for a range of willingness-
to-pay (WTP) values a decision maker would be willing to 
pay per additional DALY averted. It is evidenced that the 
probability that both intervention formats are cost-effective 
at a threshold of $50,000 per DALY averted is close to one 
(appx. 99%), with group Triple P having a high probability 
of cost-effectiveness already at very low values of WTP.
The results of the sensitivity analyses are presented in 
Table 4. The cost-effectiveness results for both interven-
tions differed little from the base-case when: assuming 
differential discount rates and assuming dropouts get 50% 
of the health benefits. The cost-effectiveness of both inter-
ventions improved greatly when assuming intervention 
effects persisted over 5 years, with group Triple P becom-
ing cost saving. The exclusion of cost offsets pertaining 
to the health sector led to slightly higher ICERs for both 
interventions compared with the base-case. The inclusion 
of time and travel costs (total time and travel costs: $2.5 M 
group; $2.8 M individual) tripled the ICER for group Triple 
P, whereas it led to individual Triple P having a slightly 
higher ICER and a lower probability of being cost-effective. 
Group Triple P became cost saving when including cost off-
sets pertaining to all sectors (cost offsets: $10.5 M group; 
$1 M individual), whereas the ICER for individual Triple P 
decreased marginally. Assuming a 50% annual decay rate of 
the intervention effect led to group Triple P becoming cost 
saving, but with a wide uncertainty interval which inter-
sected the south-east, north-east, and north-west quadrants 
of the plane—i.e., being either cost saving (dominant) or 
economically inefficient (dominated). This scenario also 
resulted in individual Triple P being more cost-effective, 
but with a wide uncertainty interval spanning over both the 
north-west and the north-east quadrants of the plane—i.e., 
Table 4  Results of univariate sensitivity analysis for the base-case model examining the cost-effectiveness of group and individual level 4 Triple 
P
a A proportion of the uncertainty iterations lie in the south-east, north-east, and the north-west quadrants of the cost-effectiveness plane, signify-
ing that there is a likelihood that the intervention is more effective and more costly than the comparator, that it is less costly and more effective 
than the comparator (dominant), and that it is more costly and less effective than the comparator (dominated)
b A proportion of the uncertainty iterations lie in both the north-west and the north-east quadrants of the cost-effectiveness plane, signifying that 
there is a likelihood that the intervention is less effective and more costly than the comparator (dominated) and that it is more costly and more 
effective than the comparator
c The intervention is less costly and more effective than the comparator (dominant)
d The intervention is less effective and more costly than the comparator (dominated)
Sensitivity analysis Group ICER (95% UI) (AU$/DALY 
averted)
Individual ICER (95% UI) 
(AU$/DALY averted)
Base-case analysis 1013 (471–1956) 20,498 (11,146–39,470)
(1) No cost offsets (health care) 2460 (1542–3871) 21,430 (11,828–40,682)
(2) With cost offsets (health care + other sector costs) Dominantc 18,527 (9564–37,207)
(3) With time and travel costs 3567 (2233–5624) 29,903 (16,532–56,903)
(4a) 50% decay in effect size over 5 years Dominantc (dominant to 2117)a 13,911  (dominatedd to 77,650)b
(4b) Full effect size extrapolated over 5 years Dominantc 2336 (1306–4009)
(5) Dropouts get 50% of health benefit 927 (477–1889) 20,248 (10,756–38,509)
(6a) Discount rate of 0% 955 (439–1779) 19,820 (10,610–38,218)
(6b) Discount rate of 6% 980 (494–2211) 20,894 (11,295–41,068)
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with a double likelihood of being less effective and more 
costly than the comparator (dominated), and more costly and 
more effective than the comparator. In the threshold analy-
sis (Fig. 3), group Triple P remained cost-effective to the 
threshold of $50,000 per DALY averted despite variations 
in effect. Individual Triple P remained below the threshold 
assuming an effect size 60% lower than the base-case. 
Further details on the sensitivity analyses are presented 
in Section 6 of the Supplementary Appendix.
Discussion
Main findings and comparison with other studies
Using the Australian population as an example, this study 
used a health care perspective to investigate the cost-effec-
tiveness of a well-known evidence-based parenting interven-
tion, group and individual face-to-face Triple P, compared 
to no intervention, for the treatment of CD in children. This 
study demonstrated that both intervention formats are good 
value for money, with the group face-to-face format having 
a higher probability of cost-effectiveness. Univariate sensi-
tivity analyses conducted corroborated the results, demon-
strating that the interventions remained cost-effective when 
making different assumptions about modelling parameters. 
The biggest impact was that of varying intervention effec-
tiveness estimates. Group Triple P remained cost-effective 
despite variations in effect, whereas the cost-effectiveness 
ratio for individual Triple P went above the threshold of 
$50,000 per DALY when assuming an effect size 60% lower 
than the base-case.
This is the first study evaluating the longer term cost-
effectiveness of parenting programmes in general and 
of Triple P in particular for the treatment of CD using a 
cost–utility framework. Bonin et al. [19] estimated the costs 
and longer term savings of parenting programmes in the UK 
associated with the reduction in the probability of persistent 
CD among children. They modelled a “generic” parenting 
intervention, based on various evidence-based programmes 
that were likely to be implemented in the UK. Their study 
demonstrated that parenting programmes were likely to 
reduce the probability of CD persisting into adulthood, as 
well as they would entail savings to the public sector in 
the short run, yielding about US$27,136 per family over 
25 years. These findings cannot, however, be compared to 
the findings of the current study, as the study from Bonin 
et al. [19] was not a full economic evaluation, but rather, 
a cost-offset scenario analysis where inputs were varied 
according to three intervention scenarios (base, best, and 
worst cases). Another similar study from Mihalopoulos et al. 
[18] modelled the expected long-term costs and cost savings 
of implementing different intensity levels of Triple P (levels 
1–5) at a population level. The study concluded that Triple 
P had the potential to be cost saving over the long-term if at 
least 7% of cases of CD were averted. Although not directly 
comparable, both studies conducted to date demonstrate the 
potential of Triple P being cost saving in the long run.
Implications for policy and practice
Clinically, while group Triple P is very cost-effective, it is 
not always possible or appropriate to provide group-based 
therapies for all families due to, for instance, limited facili-
ties, trained staff or treatment specifications per se. In this 
Fig. 3  Threshold analysis to 
examine the impact of varying 
the effect size
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instance, it is still cost-effective to provide individual-based 
Triple P, although in terms of value for health care, group-
based therapy should be the preferred mode of delivery, 
where possible.
In terms of generalizability of this study’s results, a few 
issues need to be considered. Although the context of the 
study was Australian, the methods and results have inter-
national relevance. Triple P was developed in Australia, 
but is implemented in various countries; thus, while refer-
ral pathways can differ between countries, the intervention 
itself would not differ. In our model, we assumed that the 
interventions, which were the most advanced forms of Triple 
P, were delivered by psychologists via the publicly-funded 
Medicare system. This was to reflect the common practice 
within Australian mental health services, as well as the main 
professional category likely to deliver this level of Triple P. 
It is, however, important that readers bear in mind that the 
cost-effectiveness results may be different in other settings, 
mostly due to differences between health care systems in 
terms of structure, financing, price levels, and service provi-
sion. Thus, results should be generalized only to countries 
with similar health care systems to the Australian one, such 
as the Swedish and the British one, where these interven-
tions would likely be funded publicly. Conversely, the results 
could dramatically change in contexts such as the United 
States, where such interventions are likely to be funded 
privately.
In addition, in this study, only Triple P was considered 
(although other parenting programmes have similar effect 
sizes measured using symptom scales), with the purpose of 
model testing, due to its well-established implementation in 
various international settings. Nevertheless, this model is 
flexible and can be used for economic evaluations of other 
interventions targeting CD in the Australian setting, and in 
other international settings, and thus assist priority setting.
Strengths and limitations
To the authors’ knowledge, this is the first study to assess the 
cost-effectiveness of Triple P using a cost–utility population-
based economic modelling approach. Other strengths are 
the use of the latest data on CD epidemiology; the use of a 
standardized evaluation framework to avoid methodologi-
cal confounding, and ensure comparability and transparency 
of results; and applying conservative assumptions where 
possible.
There are a few challenges to this kind of research. The 
estimates were sourced from one study each due to the lim-
ited amount of studies fulfilling our inclusion criteria. Given 
that the therapeutic content of group and individual Triple P 
is similar in terms of quantity of therapeutic time but not in 
terms of content, we would have expected individual therapy 
to be more effective than group therapy. This large difference 
in effect size is probably due to the disparity in study popula-
tion characteristics (i.e., the study on group Triple P drew 
participants from academic and general staff in a university 
setting [24]), whereas the study on individual Triple P tar-
geted low-income areas with high rates of unemployment, 
where eligible families had at least one adversity factor, such 
as maternal depression or single parenthood [25]. Families 
with more adversity factors have been shown to be less likely 
to respond to treatment [36]. With this in mind, the cost-
effectiveness of individual Triple P may have been underes-
timated and that of group Triple P overestimated.
Although the studies used to source the effectiveness 
estimates only demonstrate the effects of Triple P remain 
up to 8–10 weeks, our base-case results support the cost-
effectiveness of Triple P for the treatment of CD delivered 
within the Australian healthcare setting.
Another issue pertains to the use of symptom-based 
scales to determine clinical caseness and how well they 
reflect the true impacts of an intervention. Despite the ECBI 
being a good predictor of CD, using the cutoff as a meas-
ure of clinical caseness may underestimate the full potential 
impacts of the intervention. Impacts on children who had, 
at start, higher scores, but did not make it through the cut-
off would not be captured. We have, however, used all best 
available evidence, with this limitation in mind.
Importantly, although DALYs are acceptable to Austral-
ian decision makers [20], its use as an outcome measure 
poses limitations. The most substantial problem is the avail-
ability of a single disease weight. This makes it impossi-
ble to model changes in disease severity without making 
sweeping assumptions about the distribution of disease and 
the disability weight by severity [34] (CD does not have 
differential severity weights; for example, depression has 
differential weights for mild, moderate, and severe diseases). 
Consequently, the present study only modelled impacts of 
the interventions on diagnosed children. The study did not 
include children with sub-threshold levels of CD or with 
some levels of problems, who may also benefit from this 
intervention. Therefore, there is likely to be a substantial 
underestimation of health gains attributable to reductions 
in severity. A better approach should specify weights based 
on disease severity to reflect heterogeneity in health [37].
It is also important to appreciate that the current study 
only included impacts of the interventions on the children 
themselves, excluding any benefits that may incur to those 
directly affected by CD, such as parents, siblings, teach-
ers, and peers. A parenting intervention that successfully 
improves CD may also reduce caregiver burden and improve 
the relationship of the child with the parents and with oth-
ers in the near social circle, which will have impacts on the 
quality-of-life of these individuals. Impacts on parents are 
evidenced in the literature demonstrating that parenting 
interventions have a positive impact on parenting skills and 
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parental mental well-being [11, 16]. It is thus important that 
economic evaluation includes impacts on all relevant indi-
viduals affected by parenting interventions, so that appropri-
ate decisions can be made. Further research may be needed 
to consider this issue.
Conclusions
Evidence-based parenting programmes, such as the Triple 
P, for the treatment of CD in children, appear to represent 
good value for money, when delivered in both group and 
individual face-to-face formats, with the group format 
being the most cost-effective option. The results should, 
however, be interpreted with caution, as there are several 
limitations, including: the insufficient quality of the evidence 
for the interventions modelled and the restrictive inclusion 
of diagnosed cases of CD as the main outcome measure. 
Furthermore, the current model can be used for economic 
evaluations of other interventions targeting CD and in other 
settings.
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